Viridian Therapeutics Inc Forecast, price target & analysts
Viridian Therapeutics Inc Target price 2025 - Analyst rating & recommendation
Viridian Therapeutics Inc Classifications & Recommendation:
Viridian Therapeutics Inc Price Target
| Target Price | $40.29 |
| Price | $14.33 |
| Potential |
181.16%
register free of charge
|
| Number of Estimates | 18 |
|
18 Analysts have issued a price target Viridian Therapeutics Inc 2026 .
The average Viridian Therapeutics Inc target price is $40.29.
This is
181.16%
register free of charge
$64.05
346.96%
register free of charge
$19.19
33.91%
register free of charge
|
|
| A rating was issued by 23 analysts: 20 Analysts recommend Viridian Therapeutics Inc to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Viridian Therapeutics Inc stock has an average upside potential 2026 of
181.16%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.30 | 0.20 |
| 3.23% | 32.57% | |
| EBITDA Margin | -99,513.33% | -166,285.79% |
| 21.48% | 67.10% | |
| Net Margin | -89,983.33% | -162,584.82% |
| 17.34% | 80.68% |
16 Analysts have issued a sales forecast Viridian Therapeutics Inc 2025 . The average Viridian Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Viridian Therapeutics Inc EBITDA forecast 2025. The average Viridian Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
17 Viridian Therapeutics Inc Analysts have issued a net profit forecast 2025. The average Viridian Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.98 | -4.03 |
| 25.05% | 1.26% | |
| P/E | negative | |
| EV/Sales | 2,734.48 |
17 Analysts have issued a Viridian Therapeutics Inc forecast for earnings per share. The average Viridian Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Viridian Therapeutics Inc...
Current Viridian Therapeutics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Needham |
Locked
➜
Locked
|
Locked | May 20 2025 |
| JMP Securities |
Locked
➜
Locked
|
Locked | May 07 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | May 07 2025 |
| Needham |
Locked
➜
Locked
|
Locked | May 07 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | May 07 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 23 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Jan 07 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Needham:
Locked
➜
Locked
|
May 20 2025 |
|
Locked
JMP Securities:
Locked
➜
Locked
|
May 07 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
May 07 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
May 07 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
May 07 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 23 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Jan 07 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
